Level D· Scientific groundwork from lab and animal studiesNarrative ReviewEurope PMCOpen access

Natural products in treating sepsis-associated lung and liver injuries by mediating ferroptosis, current progress, and future perspective

Li J., Xia X., Wang K., Xu X., Li C.

Narrative Review on Scar, published in Front Pharmacol (2026) — summary generated from the PubMed abstract.

Open my reading list
Level D· Scientific groundwork from lab and animal studiesEvidence level of this study

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

  • Level A · Stronger Clinical Evidence
  • Level B · Emerging clinical evidence with positive signals
  • Level C · Early human research exploring benefits
  • Level D · Scientific groundwork from lab and animal studies
  • Emerging · Emerging topic under active research
Read the A–D evidence level guide

This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.

Study type
Narrative Review
Journal
Front Pharmacol (2026)
Reported sample size
—
Source database
Europe PMC
PMID
42232184
PMCID
PMC13223373
DOI
10.3389/fphar.2026.1785916

Abstract (original English)

Sepsis is a life-threatening disorder triggered by an unregulated host reaction to infection, and it represents a worldwide health dilemma given the scarcity of effective treatment strategies. Sepsis usually leads to lethal multiorgan dysfunctions, including acute liver failure (ALF) and acute lung injury (ALI). Recent studies have found that altered programmed cell death (PCD) processes, including apoptosis, autophagy, ferroptosis, and pyroptosis, belong to key mechanisms that trigger sepsis-associated multiorgan disorders. Among them, ferroptosis is a unique mode of PCD characterized by the accumulation of iron-dependent reactive oxygen species (ROS) and lipid peroxidation. Mediating ferroptosis is a promising strategy against sepsis. Recently, studies have identified multiple natural products for treating sepsis-associated lung and liver injuries by targeting ferroptosis. Here, we provide an overview of the mechanisms and potential therapeutic targets underlying ferroptosis in sepsis. The natural products with ferroptosis targeting will be summarized. Notably, most current evidence supporting the therapeutic potential of natural products is derived from preclinical investigations, and high-quality clinical data remain scarce, requiring further validation for clinical translation. We hope this study provides new perspectives for the future treatment of sepsis-induced ALI and

What this study does not prove

  • • This study does not prove SVF is an approved treatment or a replacement for standard care.
  • • This is a narrative review: it collects no new patient data and does not systematically appraise evidence quality.

Evidence level

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

How we grade evidence

Browse all related research

Filter the research library by this study's title keywords, author, or publication year.

Related research